drugset / Trial / NCT00770861

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861

Phase 4 Completed 277 enrolled Forest Laboratories
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension

Timeline

Start
2008-09
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nebivolol Other / unclassified 5 mg Oral
Comparator Nebivolol Other / unclassified 10 mg Oral
Comparator Nebivolol Other / unclassified 20 mg Oral
Comparator Nebivolol Other / unclassified 40 mg Oral

Indications